IL149650A0 - Novel methods for the treatment and prevention of ileus - Google Patents

Novel methods for the treatment and prevention of ileus

Info

Publication number
IL149650A0
IL149650A0 IL14965000A IL14965000A IL149650A0 IL 149650 A0 IL149650 A0 IL 149650A0 IL 14965000 A IL14965000 A IL 14965000A IL 14965000 A IL14965000 A IL 14965000A IL 149650 A0 IL149650 A0 IL 149650A0
Authority
IL
Israel
Prior art keywords
ileus
methods
prevention
treatment
novel methods
Prior art date
Application number
IL14965000A
Other languages
English (en)
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of IL149650A0 publication Critical patent/IL149650A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14965000A 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus IL149650A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45092099A 1999-11-29 1999-11-29
PCT/US2000/042313 WO2001042207A2 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus

Publications (1)

Publication Number Publication Date
IL149650A0 true IL149650A0 (en) 2002-11-10

Family

ID=23790061

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14965000A IL149650A0 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus
IL149650A IL149650A (en) 1999-11-29 2002-05-14 Piperidine n-alkylcarboxylate compounds for use as medicaments for the treatment and prevention of ileus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149650A IL149650A (en) 1999-11-29 2002-05-14 Piperidine n-alkylcarboxylate compounds for use as medicaments for the treatment and prevention of ileus

Country Status (14)

Country Link
EP (1) EP1244448B1 (https=)
JP (2) JP5079961B2 (https=)
AT (1) ATE432076T1 (https=)
AU (2) AU780738B2 (https=)
CA (1) CA2393141C (https=)
CY (1) CY1109264T1 (https=)
DE (1) DE60042282D1 (https=)
DK (1) DK1244448T3 (https=)
ES (1) ES2329004T3 (https=)
IL (2) IL149650A0 (https=)
MX (1) MXPA02005336A (https=)
NZ (1) NZ518684A (https=)
PT (1) PT1244448E (https=)
WO (1) WO2001042207A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP5176188B2 (ja) 2006-04-21 2013-04-03 ディーエスエム アイピー アセッツ ビー．ブイ． オピオイド受容体拮抗薬の使用
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2455943C1 (ru) * 2011-02-01 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ лечения обтурационной формы острой спаечной тонкокишечной непроходимости

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (de) * 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
EP0103636B1 (en) * 1982-03-16 1990-09-12 Rockefeller University Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds

Also Published As

Publication number Publication date
JP2003517476A (ja) 2003-05-27
JP5460771B2 (ja) 2014-04-02
EP1244448A2 (en) 2002-10-02
CA2393141A1 (en) 2001-06-14
ATE432076T1 (de) 2009-06-15
AU3970501A (en) 2001-06-18
AU2005203041A1 (en) 2005-08-04
DE60042282D1 (de) 2009-07-09
ES2329004T3 (es) 2009-11-20
PT1244448E (pt) 2009-06-30
CY1109264T1 (el) 2014-07-02
MXPA02005336A (es) 2003-01-28
AU780738B2 (en) 2005-04-14
DK1244448T3 (da) 2009-08-17
EP1244448A4 (en) 2003-06-25
JP2012162560A (ja) 2012-08-30
IL149650A (en) 2011-02-28
EP1244448B1 (en) 2009-05-27
JP5079961B2 (ja) 2012-11-21
WO2001042207A3 (en) 2002-05-02
AU2005203041B2 (en) 2009-01-08
CA2393141C (en) 2013-08-13
NZ518684A (en) 2003-11-28
WO2001042207A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
CY1109264T1 (el) Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου
WO2001041705A3 (en) Novel methods for the treatment and prevention of dizziness and pruritus
HK1055078A1 (zh) 使用纳布啡和鸦片拮抗剂治疗疼痛的方法
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
IL149378A0 (en) Composition for treatment of constipation and irritable bowel syndrome
NZ331001A (en) Use of an opiate K receptor agonist as an antipruritic
WO2003070191A8 (en) Tamper-resistant transdermal opioid delivery devices
WO2004096122A3 (en) Use of ngf antagonists and opioids for treating pain
DE69841663D1 (de) Verwendung von methylnaltrexon und verwandten verbindungen
CA2312234A1 (en) Use of methylnaltrexone and related compounds
AU5914201A (en) Intrathecal administration of rituximab for treatment of central nervous system lymphomas
RU2000119779A (ru) Способ предотвращения злоупотребления содержащими опиоиды лекарственными формами
CA2548834A1 (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
EP0915094A4 (en) MORPHINANE DERIVATIVES AND MEDICAL USE THEREOF
MXPA03007885A (es) Norbuprenorfina n-but-3-enilo y metodos de uso.
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
CA2430281A1 (en) Use of weak opioids and mixed opioid agonists/antagonists for treatment of urinary incontinence
BG106831A (en) Compound and method for the treatment of pain
HK1080004A (en) Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
IT1260498B (it) Composizioni terapeutiche a rilascio ritardato atte ad inibire l'assunzione di oppiacei

Legal Events

Date Code Title Description
FF Patent granted